Egen Atkinson

Co-Founder and Managing Partner

Michael Kramarz

Co-Founder and Managing Partner

26 past transactions

Neurogene

Post in 2024
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.

IDRx

Series B in 2024
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.

Avalo Therapeutics

Post in 2024
Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.

Nkarta Therapeutics

Post in 2024
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cells for the treatment of cancer and autoimmune diseases. The company aims to enhance the efficacy of cell therapy by leveraging the inherent ability of NK cells to identify and eliminate abnormal cells without the need for genetic alteration. This approach allows for a broader application across various hematologic and solid tumor malignancies while potentially minimizing side effects associated with traditional T-cell therapies. Nkarta combines its NK expansion platform technology with proprietary cell engineering methods to produce a substantial supply of NK cells, enhancing their ability to recognize therapeutic targets and improving their persistence in the body for sustained activity. Through this innovative strategy, Nkarta seeks to provide more potent, well-tolerated, and rapidly available therapies for patients facing diverse cancer types.
Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing small molecule therapies aimed at improving patients' lives. Founded in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a discovery process that integrates clinically validated biological targets with advanced chemistry to create innovative oncology therapeutics. Enliven's product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and combat wild-type HER2. The company's therapeutic programs address critical challenges in oncology, such as tolerability, resistance, and disease escape, particularly in patients with brain metastases.

MindMed

Post in 2024
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

Cogent Biosciences

Post in 2024
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.
Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. The company's pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-lasting therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with Editas Medicine to utilize its proprietary AAV vectors for gene editing in inherited retinal diseases, and with Regeneron Pharmaceuticals for developing various ocular therapies. Founded in 2006 and headquartered in Redwood City, California, Adverum aims to establish gene therapy as a new standard of care, aspiring to restore vision and prevent blindness in affected patients.

Spyre Therapeutics

Post in 2023
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

SAB Biotherapeutics

Post in 2023
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and disorders of the central nervous system, particularly those related to psychiatric conditions such as depression and anxiety. The company's main product candidates include PH94B, a neuroactive nasal spray poised for Phase III trials aimed at treating acute anxiety in adults with social anxiety disorder, and PH10, another nasal spray in preparation for Phase 2b development for major depressive disorder. Additionally, AV-101, an oral prodrug candidate, is being developed for multiple indications, including major depressive disorder, suicidal ideation, and neuropathic pain. VistaGen has established various licensing and collaboration agreements with other firms to enhance its research and development efforts, including a strategic partnership for the clinical development of PH94B in select Asian markets. Founded in 1998, VistaGen is headquartered in South San Francisco, California.

Soleno Therapeutics

Post in 2023
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome (PWS). This product is currently undergoing evaluation in a Phase III clinical development program. Soleno Therapeutics was incorporated in 1999 and is based in Redwood City, California. The company was previously known as Capnia, Inc. before rebranding in May 2017.

Abivax

Post in 2023
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.

Immunovant

Post in 2022
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

Allakos

Post in 2022
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Celcuity

Post in 2022
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.

Third Harmonic Bio

Series B in 2022
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.

Nimbus Apollo

Venture Round in 2021
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Shoreline Biosciences

Venture Round in 2021
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA.

Cogent Biosciences

Post in 2020
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.